Dermatology RSS : Gourt

Ideal Metropolitan Tampa Location for this General Dermatology Opportunity :: Florida :: CompHealth Inc

Job 915566 Join this single specialty group on the partnership track. Competitive compensation, sign on bonus and a waiting patient base all combine to make this a great opportunity. Board Certified

Beautiful north woods City in Minnesota seeks a General Dermatologist :: Minnesota :: CompHealth Inc

Job 917271 Seeking second Dermatologist to join this well respected MSG General Dermatology practice that has surgical and cosmetic components Full range of ancillary services including a phototherapy

Clear Blue Lakes and a $50,000 signing incentive in North Dakota! :: North Dakota :: CompHealth Inc

Job 917272 Join an expanding practice in a with the leader in the health care industry In your practice you will see a wide range of dermatologic disorders The cosmetic practice utilizes state-of-the-art

Join a Five (5) person Dermatology group in Metro North Carolina :: North Carolina :: CompHealth Inc

Job 917626 A very renouned and respected Dermatology group is looking for you in North Carolina Receive wonderfully competitive base income Earning potential with this group depends on how much you

Dermatologist needed in highly sought after Texas location. :: Texas :: CompHealth Inc

Job 917708 Practice Dermatology in one of the best places to live in all Texas for a Top Notch Dermatology group. Incoming physician will be the 2nd Dermatologist to join this new state of the are 2800sqft

The sky's the limit between Lexington and Cincinnati! :: Kentucky :: CompHealth Inc

Job 612492 Practice Dermatology the way you want to in Kentucky Growing market needs a full time Dermatologist Hospital sponsored solo start up Huge income guarantee year one 100% relocation covered

Great Dermatology Opportunity Just Outside of Boston :: Massachusetts :: CompHealth Inc

Job 915578 NO weekends, close to Boston Highly competitive base salary Huge earning potential Admit to only 1 hospital Possible sign on bonus Life insurance Relocation and 401K 4 weeks vacation plus

Excellent Dermatology opportunity in New York City :: New York :: CompHealth Inc

Job 917248 Join this wonderful two (2) person group with excellent work schedule in the city Excellent and competitive income Group is booked out months and need great help Terrific lifestyle with everything

Dermatologist Needed in the Mount Rushmore State :: South Dakota :: CompHealth Inc

Job 3110488 Become the first dermatologist in this untapped market! Hugh income potential Seven-county untapped market Waiting patient base Relocation fully paid No state taxes 80% private insurance,

Great Northwest Dermatology Opportunity Awaits :: Illinois :: CompHealth Inc

Job 917167 Be the first General Dermatologist to join this group 2008 Candidates Welcome Large Referral Base No Call Schedule Low Crime rates & Cost of Living Great Schools, Proximity to Lakes and

Fantastic Dermatology opportunity in Indiana! :: Indiana :: CompHealth Inc

Job 916786 Be the first, and only, Dermatologist with this multi specialty group with referral! This is a bread and butter opportunity Excellent referral base from the group Very competitive base salary

Great Dermatology Opportunity in Oregon! :: Oregon :: CompHealth Inc

Job 915563 Fast partnership track with huge base income near Portland, Oregon. Lavish and liberal bonus Excellent incentive bonuses Huge earning potential Quick track to partnership Very beautiful college

Excellent dermatology job in Minnesota. :: Minnesota :: CompHealth Inc

Job 915993 Join other Dermatologists in this unique practice with all benefits in place. Very attractive base salary Huge earning potential Open sign on bonus Possible loan repayment Fast track to membership

Unique Dermatology opportunity in Ohio :: Ohio :: CompHealth Inc

Job 916008 Fast Partnership track in this huge referral based practice!! Enjoy a great work schedule Receive very competitive salary Huge income base potential Malpractice is paid in full Prepare for

Dermatology at the city on the lakes :: New Hampshire :: CompHealth Inc

Job 917627 Lucrative opportunity! Replace local retired Dermatologist and be busy from day one. Will be the only Dermatologist in a service area of 100k and no call. Make a lot of money but have a life

Join a premiere group in Wisconsin! :: Wisconsin :: CompHealth Inc

Job 916294 Become part of a very well respected group in the Badger state! Worry free employed position General derm with option of dermatologic surgery Very affordable cost of living Option to teach

Incredible Dermatology Opportunity :: New York :: CompHealth Inc

Job 916891 Dermatologist needed in New York due to growing patient base. Huge Opportunity! Work Monday - Friday 8:00 am to 5:00 pm No Call Starting Base Salary $300k to $350k (DOE) with production bonus

One of a kind Mohs opportunity :: Wisconsin :: CompHealth Inc

Job 917680 A 35 year old SSG Dermatology group under new ownership for the past 5 years is seeking a Mohs Surgeon. This is a one of a kind opportunity for the incoming Mohs Surgeon with a 300k service

Call for Information :: California :: Inhouse Physician Recruiters Network

The In-House Physician Recruiter Network, composed of over 500 hospital recruiters, represents over 10,000 hospitals and clinics. Our Network's special feature is to showcase outstanding physicians (who

Call for Information :: North Carolina :: Inhouse Physician Recruiters Network

About This Journal [About This Journal]

This Month in Archives of Dermatology [This Month in Archives of Dermatology]

Idiopathic Multiple Haemorrhagic Sarcoma (Kaposi): Trauma an Aetiological Factor (?) [Archives a Century Ago]

Leflunomide in the Treatment of Palmoplantar Pustulosis [The Cutting Edge]

Text-Message Reminders to Improve Sunscreen Use: A Randomized, Controlled Trial Using Electronic Monitoring [Study]

Objective To evaluate the effectiveness of cellular telephone text messaging as a reminder tool for improving adherence to sunscreen application. Design We conducted a randomized, controlled trial of the effect of an electronic text-message reminder system on adherence to sunscreen application. Adherence to daily sunscreen use was evaluated using a novel electronic monitoring device. Setting Participants were recruited from the general community. Participants Seventy participants constituted a volunteer sample from the general community. The inclusion criteria required participants to be 18 years or older, to own a cellular telephone with text-message features, and to know how to retrieve text messages. Intervention Half of the participants received daily text-message reminders via cellular telephone for 6 weeks, and the other half did not receive reminders. The text-message reminders consisted of 2 components: a "hook" text detailing daily local weather information and a "prompt" text reminding users to apply sunscreen. Main Outcome Measure The primary end point of the study was adherence to sunscreen application measured by the number of days participants applied sunscreen during the 6-week study period. Results All 70 participants completed the 6-week study. There were no statistically significant differences in baseline characteristics between the 2 study groups. At the end of the study period, the 35 participants who did not receive reminders had a mean daily adherence rate of 30.0% (95% confidence interval, 23.1%-36.9%). In comparison, the 35 participants who received daily text-message reminders had a mean daily adherence rate of 56.1% (95% confidence interval, 48.1%-64.1%) (P < .001). Among the participants in the reminder group, 24 (69%) reported that they would keep using the text-message reminders after the study, and 31 (89%) reported that they would recommend the text-message reminder system to others. Subgroup analysis did not reveal any significant demographic factors that predicted adherence. Conclusions Despite awareness of the benefits of sunscreen, adherence is low, even in this population, for whom adherence was knowingly monitored. Short-term data demonstrate that using existing cellular telephone text-message technology offers an innovative, low-cost, and effective method of improving adherence to sunscreen application. The use of ubiquitous communications technology, such as text messaging, may have implications for large-scale public health initiatives. Trial Registration clinicaltrials.gov Identifier: NCT00535769

Elevated D-dimer Level in the Differential Diagnosis of Venous Malformations [Study]

Objective To evaluate if elevated D-dimer level is specific for venous malformations (VMs) and thus useful for differential diagnosis, which can be problematic even in specialized interdisciplinary centers. Localized intravascular coagulopathy, characterized by elevated D-dimer levels, has been observed in approximately 40% of patients with VMs. Design Prospective convenience sample accrued from 2 interdisciplinary sites. Setting Two interdisciplinary centers for vascular anomalies in Brussels, Belgium, and Caen, France Participants The study population comprised 280 patients with clinical data, Doppler ultrasonograms (for 251 patients), and coagulation parameter measurements. Main Outcome Measure Measurement of D-dimer levels. Results A VM was diagnosed in 195 of 280 patients (69.6%), and 83 of them had elevated D-dimer levels; the sensitivity of D-dimer dosage was 42.6% (95% confidence interval, 35.6%-49.5%). Among the 85 patients without VM, D-dimer levels were elevated only in 3 patients; the specificity of the dosage was 96.5% (95% confidence interval, 92.5%-100%). Conclusions Elevated D-dimer level is highly specific for VMs (pure, combined, or syndromic), and therefore this easy and inexpensive biomarker test should become part of the clinical evaluation of vascular anomalies. It can detect hidden VMs and help differentiate glomuvenous malformation (normal D-dimer levels) from other multifocal venous lesions. Elevated D-dimer level also differentiates a VM from a lymphatic malformation. Moreover, slow-flow Klippel-Trenaunay syndrome (capillaro-lymphatico-venous malformation with limb hypertrophy) can be distinguished from fast-flow Parkes Weber syndrome (capillary malformation with underlying multiple microfistulas and limb hypertrophy). For these reasons, D-dimer level measurement is a useful complementary tool for diagnosing vascular anomalies in everyday practice.

Analysis of Globule Types in Malignant Melanoma [Study]

Objective To identify and analyze subtypes of globules based on size, shape, network connectedness, pigmentation, and distribution to determine which globule types and globule distributions are most frequently associated with a diagnosis of malignant melanoma. Design Retrospective case series of dermoscopy images with globules. Setting Private dermatology practices. Participants Patients in dermatology practices. Intervention Observation only. Main Outcome Measure Association of globule types with malignant melanoma. Results The presence of large globules (odds ratio [OR], 5.25) and globules varying in size (4.72) or shape (5.37) had the highest ORs for malignant melanoma among all globule types and combinations studied. Classical globules (dark, discrete, convex, and 0.10-0.20 mm) had a higher risk (OR, 4.20) than irregularly shaped globules (dark, discrete, and not generally convex) (2.89). Globules connected to other structures were not significant in the diagnosis of malignant melanoma. Of the different configurations studied, asymmetric clusters have the highest risk (OR, 3.02). Conclusions The presence of globules of varying size or shape seems to be more associated with a diagnosis of malignant melanoma than any other globule type or distribution in this study. Large globules are of particular importance in the diagnosis of malignant melanoma.

August 2009 Archives Web Quiz Winner [Archives Web Quiz Winner]

Factors Contributing to Incomplete Excision of Nonmelanoma Skin Cancer by Australian General Practitioners [Study]

Objective To study rates of incomplete excision of basal (BCC) and squamous (SCC) cell cancer by Australian general practitioners with a special interest. Design Records review. Setting A network of 15 primary care skin cancer clinics across Australia. Participants Fifty-seven physicians performing excisions of 9417 BCCs and SCCs in a single network of 15 primary care skin cancer clinics across Australia between 2005 and 2007. Main Outcome Measures Rates of incomplete excision according to physician, clinic, anatomic location of the lesion, and whether a previous biopsy had been performed. Results Four hundred forty-three of 6881 BCCs (6.4%) and 159 of 2536 SCCs (6.3%) were excised incompletely. Incomplete BCC and SCC excisions were more frequent on the head and neck (282 of 2872 excisions [9.8%] and 97 of 861 [11.3%], respectively) than elsewhere. Ears (74 of 388 excisions [19.1%]) and nose (78 of 546 [14.3%]) had the highest rates of incompletely excised BCCs, and ears (26 of 144 excisions [18.1%]) and forehead (20 of 157 [12.7%]) had the highest rates of incompletely excised SCCs. Of all BCC excisions, 67.3% were once-off excisions with no previous biopsy, and these excisions were more likely to be incomplete (odds ratio, 1.73; 95% confidence interval, 1.36-2.20) than those with a previous biopsy. There was, however, substantial variation in frequency of incomplete excision between clinics for BCC (ranging from 3.3% to 24.7%) and SCC (ranging from 0% to 17.2%) and between physicians within clinics (BCC ranging from 0% to 31.1%, and SCC ranging from 0% to 23.5%). Conclusions Overall frequency of incomplete excision is low and similar to that in other reports. However, high frequency in high-risk sites, low rates of previous biopsy, and substantial variation in performance between physicians and clinics suggests there is significant opportunity to further improve health outcomes.

Alefacept for Severe Alopecia Areata: A Randomized, Double-blind, Placebo-Controlled Study [Study]

Objective To assess the efficacy of alefacept for the treatment of severe alopecia areata (AA). Design Multicenter, double-blind, randomized, placebo-controlled clinical trial. Setting Academic departments of dermatology in the United States. Participants Forty-five individuals with chronic and severe AA affecting 50% to 95% of the scalp hair and resistant to previous therapies. Intervention Alefacept, a US Food and Drug Administration–approved T-cell biologic inhibitor for the treatment of moderate to severe plaque psoriasis. Main Outcome Measure Improved Severity of Alopecia Tool (SALT) score over 24 weeks. Results Participants receiving alefacept for 12 consecutive weeks demonstrated no statistically significant improvement in AA when compared with a well-matched placebo-receiving group (P = .70). Conclusion Alefacept is ineffective for the treatment of severe AA.

Topical Calcipotriol for Preventive Treatment of Hypertrophic Scars: A Randomized, Double-blind, Placebo-Controlled Trial [Study]

Objectives To evaluate the efficacy of topical application of calcipotriol to healing wounds in preventing or reducing hypertrophic scar formation and to investigate the biochemical properties of the epidermis associated with hypertrophic scar formation. Design Randomized, double-blind, placebo-controlled trial using the reduction mammoplasty wound-healing model. Setting University Medical Center Groningen. Patients Thirty women who underwent bilateral reduction mammoplasty. Interventions For 3 months, scar segments were treated with either topical calcipotriol or placebo. Main Outcome Measures Three weeks, 3 months, and 12 months postoperatively, the scars were evaluated and punch biopsy samples were collected for immunohistochemical analysis. Results No significant difference in the prevalence of hypertrophic scars was observed between the placebo- and calcipotriol-treated scars. Only scars with activated keratinocytes 3 weeks postoperatively became hypertrophic (P = .001). Conclusions Topical application of calcipotriol during the first 3 months of wound healing does not affect the incidence of hypertrophic scar formation. We observed a strong association between keratinocyte activation and hypertrophic scar formation. Trial Registration trialregister.nl Identifier: NTR1486

Tumor Mapping in 2 Large Multigenerational Families With CYLD Mutations: Implications for Disease Management and Tumor Induction [Study]

Objectives To comprehensively ascertain the extent and severity of clinical features in affected individuals from 2 large families with proven heterozygous mutations in the CYLD locus and to correlate these findings with the 3 appendageal tumor predisposition syndromes (familial cylindromatosis, Brooke-Spiegler syndrome, and multiple familial trichoepitheliomas) known to be associated with such germline mutations. Design Interfamilial and intrafamilial observational study. Setting Tertiary genetic and dermatology referral center. Participants Thirty-four individuals recruited from 2 large multigenerational families with CYLD mutations. Clinical details, history, and tumor maps were obtained from all participants; in 18, the information was corroborated by detailed clinical examination. Main Outcome Measures Tumor density, distribution and histologic findings, associated medical conditions, patient symptoms, and impact of disease on quality of life. Results The severity of penetrance and phenotype varied within families. Although an approximately equal female to male predisposition was noted, 5 women and 1 man (of 26 patients surveyed [23%]) had undergone total scalp removal. The average age at onset was 16 years (range, 8-30 years). Symptoms reported by affected patients included painful tumors (in 12 of 23 patients [52%] who answered the question), conductive deafness, and sexual dysfunction. Of the 26 surveyed patients, tumors were noted on the scalp in 21 (81%), on the trunk in 18 (69%), and in the pubic area in 11 (42%). Tumor mapping provided clinical evidence that correlated with hormonally stimulated hair follicles being particularly vulnerable to loss of heterozygosity and tumor induction. Conclusions The burden of disease at sites other than the head and neck appears to be underreported in the literature and greatly affects quality of life. Differentiation between the clinical diagnoses has little prognostic or clinical utility in genetic counseling, even within individuals from the same family. Thus, we suggest an encompassing diagnosis of "CYLD cutaneous syndrome." Finally, the clinical distribution of tumors suggests that hormonal factors may play an important role in tumor induction in these patients.

Unexpected Occurrence of Xeroderma Pigmentosum in an Uncle and Nephew [Observation]

Background Xeroderma pigmentosum (XP) is a rare autosomal recessive disorder characterized by a decreased ability to repair DNA damaged by UV radiation and the early development of cutaneous and ocular malignant neoplasms. Approximately 20% of patients with XP also develop progressive neurologic degeneration. Observations We describe a boy who was found to have XP after a severe burn following minimal sun exposure. His maternal uncle, now age 20 years, had been diagnosed with XP after a similar sunburn in infancy. The uncle has the typical skin pigmentary findings of XP along with severe progressive neurologic involvement. Although the infant's parents were not known to be blood relatives, the infant and his affected uncle proved to be compound heterozygotes for the same 2 frameshift mutations in the XPA DNA repair gene (c.288delT and c.349_353del). After the diagnosis of XP in the infant, genealogic investigation identified a common Dutch ancestor for both of his grandfathers 5 generations back. Conclusions Counseling families at risk for a rare inherited disease is not always straightforward. The sociocultural and demographic backgrounds of the families must be considered for evaluation of risk assessment.

Omitted Author Name in: Primary Treatment of Verrucous Carcinoma of the Penis With Fluorouracil, cis-Diamino-dichloro-platinum, and Radiation Therapy [Correction]

Granulomatous Dermatitis With Pseudoxanthoma Elasticum-Like Changes: Report of a Case in a Patient With Cystic Fibrosis [Observation]

Background There is scant literature that documents pseudoxanthoma elasticum (PXE)–like histologic changes in the setting of inflammatory skin diseases. This article documents granulomatous dermatitis with PXE-like changes in a patient with cystic fibrosis. This is the first report of its kind, to our knowledge. Observations A 33-year-old woman with cystic fibrosis developed a papular eruption on the flexural surfaces of the upper and lower extremities, which was initially treated with prednisone. A punch biopsy showed granulomatous inflammation and associated PXE-like changes. The combined histologic and clinical findings were most consistent with granuloma annulare. There was no family history of PXE or clinical manifestations of PXE. The rash gradually resolved itself over the next several months. Conclusions There are few publications that document PXE-like changes in association with various inflammatory skin conditions. Thus, the clinical significance of this finding remains uncertain. This case and previous reports are discussed in the context of current molecular and genetic knowledge. It is hoped that greater awareness of this phenomenon will promote further investigation and elucidation of the clinical and biologic significance of PXE-like changes observed in biopsies of inflammatory skin disorders.

July 2009 Archives Web Quiz Winner [Archives Web Quiz Winner]

Aquagenic Wrinkling of the Palms in Cystic Fibrosis: Comparison With Controls and Genotype-Phenotype Correlations [Observation]

Objective To determine the prevalence of aquagenic wrinkling of the palms (AWP) in patients with cystic fibrosis (CF) compared with control patients, and evaluate for genotype-phenotype correlations. Since its first description over 30 years ago, AWP has frequently been anecdotally associated with CF, but this association has not been confirmed in a rigorous prospective case-control study. Design Blinded comparison. Setting The CF and dermatology clinics at St Louis Children's Hospital. Participants Forty-four individuals with CF from a CF clinic and 26 controls from a dermatology clinic. Intervention Participants were tested for AWP using 3 minutes of water immersion with room-temperature tap water. Main Outcome Measure The degree of AWP was scored from 0 (no wrinkling) to 4 (severe wrinkling) by 3 blinded physicians. For genotype-phenotype correlations, patients with CF were divided into those homozygous for the F508 mutation and those with other genotypes. Results The mean AWP score of the CF group was significantly higher than the mean score of the control group (1.5 vs 0.6; P < .001). Patients with CF who were homozygous for the F508 mutation (n = 27) had significantly higher scores than patients with CF who were not homozygous for the F508 mutation (n = 17) (1.7 vs 1.1; P = .02). The 17 patients with CF who were not homozygous for the F508 mutation still had higher scores than the control group (1.1 vs 0.6; P = .03). There was no correlation between sweat chloride concentrations measured at the time of diagnosis and AWP score. Conclusions Our results confirm the association between AWP and CF. Among patients with CF, greater AWP occurs in those who are homozygous for the F508 mutation.

Pulsed High-Dose Corticosteroids Combined With Low-Dose Methotrexate Treatment in Patients With Refractory Generalized Extragenital Lichen Sclerosus [Observation]

Background Lichen sclerosus (LS) is a rare, chronic inflammatory skin disease that predominantly affects the anogenital area. A few patients exhibit widespread extragenital disease that may lead to blister formation and superficial erosions. We evaluated the efficacy of pulsed high-dose corticosteroids combined with low-dose methotrexate treatment in patients with refractory generalized LS that had failed to respond to standard topical corticosteroid therapy. Observation Seven patients were included in this retrospective study, all of whom were treated with pulsed high-dose corticosteroids combined with low-dose methotrexate for at least 6 months. The outcome measure was an individual, nonvalidated clinical score. Overall, a significant decrease in the clinical score was observed, from a median score of 8 (range, 5 to 24) before treatment to 2 (range, 1 to 4) after treatment. Adverse effects observed during therapy were moderate and disappeared after the end of treatment. During the follow-up period of at least 3 months (mean, 4.7 [range, 3-8] months), none of the patients experienced a relapse of extragenital LS. Conclusions Patients with severe extragenital LS benefit from pulsed high-dose corticosteroids combined with low-dose methotrexate therapy. This combination therapy should be considered in generalized disease, especially disease that is refractory to conventional treatment.

The Balm of Gilead [Notable Notes]

Delayed Inflammatory Reaction to Bio-Alcamid Polyacrylamide Gel Used for Soft-Tissue Augmentation [Observation]

Background Given the recent boom of the cosmetic industry, there is a wealth of new products available to patients and physicians, including soft-tissue fillers. Bio-Alcamid polyacrylamide gel (Polymekon, Milan, Italy) is a filler that has potential to cause adverse reactions. Observations Two patients who had previously been treated with Bio-Alcamid outside of the United States presented with different manifestations of inflammatory responses to the product. These reactions were challenging to treat. Conclusions Despite claims of safety, Bio-Alcamid and possibly other soft-tissue fillers available worldwide have the potential to cause adverse reactions. Physicians should be aware of the various presentations and treatment options for these reactions.

Disappearance of Lentigines in a Patient Receiving Imatinib Treatment for Familial Gastrointestinal Stromal Tumor Syndrome [Observation]

Background Gastrointestinal stromal tumors (GISTs) harbor gain-of-function mutations of the c-kit tyrosine kinase receptor. Imatinib mesylate is an inhibitor of c-kit and is indicated in the treatment of chronic myeloid leukemia and GISTs. Reported adverse effects of imatinib include hypopigmentation, depigmentation, and hyperpigmentation. Although the exact mechanism by which these occur is unclear, it is likely that inhibition of c-kit leads to downstream inhibition of the tyrosinase gene promoter and thus to inhibition of pigment production. Observations A 45-year-old woman with a history of multiple dysplastic nevi and lentigines was diagnosed as having familial GIST syndrome. Treatment with imatinib mesylate was started in an attempt to decrease the tumor load. Three months after treatment initiation, the patient noted a decrease in the number of pigmented lesions, lightening of the skin in her genital area, and graying of her terminal hair. Conclusions The potential association between a specific genetic mutation and pigmentation changes secondary to imatinib therapy may account for the variety in presentation of this potential side effect. Further genetic studies paired with melanocyte-specific or c-kit–specific stains of affected tissue are warranted to better understand the relationship between the genetic mutation and the effect of imatinib on pigmentation.

Adherence, the Fourth Dimension in the Geometry of Dermatological Treatment [Editorial]

Relevance of D-dimer Testing in Patients with Venous Malformations [Editorial]

A Rapidly Growing Lesion on the Lip--Quiz Case [Off-Center Fold]

A Rapidly Growing Lesion on the Lip--Diagnosis [Off-Center Fold]

Fleshy Facial Lesion on an 80-Year-Old Dayak Woman--Quiz Case [Off-Center Fold]

Fleshy Facial Lesion on an 80-Year-Old Dayak Woman--Diagnosis [Off-Center Fold]

Asymptomatic Nodules on the Foot--Quiz Case [Off-Center Fold]

Asymptomatic Nodules on the Foot--Diagnosis [Off-Center Fold]

Confluent Scaly Erythematous Plaques on the Trunk of a 16-Year-Old Boy--Quiz Case [Off-Center Fold]

Confluent Scaly Erythematous Plaques on the Trunk of a 16-Year-Old Boy--Diagnosis [Off-Center Fold]

The Whiteboard Marker as a Useful Tool for the Dermoscopic "Furrow Ink Test" [Research Letters]

Severe and Unrecognized Dental Abnormalities After Drug-Induced Epidermal Necrolysis [Research Letters]

No Biopsy Needed for Eclipse and Cockade Nevi Found on the Scalps of Children [Research Letters]

The Management of Severe Ocular Complications of Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis [Correspondence]

The Management of Severe Ocular Complications of Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis--Reply [Correspondence]

Linking Publication About Efalizumab Effectiveness With Safety Concerns [Correspondence]

Leukonychia Related to Vorinostat [Correspondence]

An Association of Idiopathic Chronic Eosinophilic Pneumonia With Pemphigoid Nodularis: A Rare Variant of Bullous Pemphigoid [Correspondence]

Erosive Pustular Dermatosis of the Scalp Following Treatment With Topical Imiquimod for Actinic Keratosis [Correspondence]

Cutaneous Epidermal Cysts as a Presentation of Gorlin Syndrome [Correspondence]

Volunteering With Health Volunteers Overseas [Announcement]

Perifollicular White Halo: A Dermoscopic Subpattern of Melanocytic and Nonmelanocytic Skin Lesions [skINsight]